camostat has been researched along with Libman-Sacks Disease in 1 studies
camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ueda, Y | 1 |
| Nagasawa, K | 1 |
| Tsukamoto, H | 1 |
| Horiuchi, T | 1 |
| Yoshizawa, S | 1 |
| Tsuru, T | 1 |
| Furugo, I | 1 |
| Niho, Y | 1 |
1 trial available for camostat and Libman-Sacks Disease
| Article | Year |
|---|---|
Urinary C4 excretion in systemic lupus erythematosus.
Topics: Adolescent; Adult; Blotting, Western; Complement Activation; Complement C4; DNA; Esters; Female; Gab | 1995 |